Abstract:GnRH antagonists (GnRH-Ants) have been demonstrated to reduce endometriosis-associated pain. As a direct consequence of the hypoestrogenic state they induce, however, when used at higher dosages GnRH-Ants are not recommended for long-term use This unwanted effect may be eliminated by the so-called add-back therapy. This review was conducted to assess the safety and efficacy of GnRH-Ants, with or without add-back hormonal replacement therapy (ABT). Out of the 345 studies selected through the initial search, seven randomized-controlled trials were included, comparing different oral GnRH-ants at varying dosages, from a minimum of 50 mg to a maximum of 200 mg once/twice daily. Women treated with GnRH-Ants at the lowest dose had significantly higher mean pain score reductions from baseline throughout treatment as compared with those treated with placebo (OR=-13.12, 95% CI=(-17.35, -8.89) and (OR= -3.08, 95%CI =(-4.39, -1.76) for dysmenorrhea and non-menstrual pelvic pain, respectively . Compatibly with the dose-response effect, we found a positive correlation between responsive rates and adverse events rates. While GnRH-Ants offer an advantage in terms of pain reduction for endometriosis, the more recent literature suggests the use of GnRH-Ants with ABT which, while mitigating the hypoestrogenic effects of GnRH-Ants, maintain their efficacy, while allowing their long-term use.

Why do estrogens matter: a systematic review and meta-analysis on use of gnrh antagonists, with or without add-back therapy, for endometriosis-associated pain